{"id":168657,"date":"2025-06-05T06:38:38","date_gmt":"2025-06-05T10:38:38","guid":{"rendered":"https:\/\/44.250.171.167\/?p=168657"},"modified":"2025-06-05T06:38:38","modified_gmt":"2025-06-05T10:38:38","slug":"akums-drugs-12-rise-in-revenue","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/akums-drugs-12-rise-in-revenue\/","title":{"rendered":"Akums Drugs &#038; Pharmaceuticals Ltd Q4FY25; 12% rise in Revenue"},"content":{"rendered":"<p>Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.<\/p>\n<p>Financial Results:<\/p>\n<p>Akums Drugs &amp; Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b91,056.00 Crores up from \u20b9944.00 Crore year on year, a rise of 11.86%.<\/p>\n<p>Total Expenses for Q4FY25 of \u20b91,007.00 Crores up from \u20b9987.00 Crores year on year, a rise of 2.03%.<\/p>\n<p>Consolidated Net Profit of \u20b9150.00 Crores from -\u20b939.00 Crores in the same quarter of the previous year.<\/p>\n<p>The Earnings per Share is \u20b99.38, from -\u20b92.89 in the same quarter of the previous year.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-168658\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png\" alt=\"\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services. Financial Results: Akums Drugs &amp; Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b91,056.00 Crores up from \u20b9944.00 Crore year on year, a rise of 11.86%. Total Expenses for Q4FY25 [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":168658,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[1115],"class_list":["post-168657","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170544,"url":"https:\/\/alphastreet.com\/india\/akums-q1-fy26-earnings-results\/","url_meta":{"origin":168657,"position":0},"title":"Akums Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AKUMS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169071,"url":"https:\/\/alphastreet.com\/india\/emcure-pharmaceuticals-ltd-q4fy25-63-rise-in-profits\/","url_meta":{"origin":168657,"position":1},"title":"Emcure Pharmaceuticals Ltd Q4FY25; 63% rise in Profits","author":"Divyansh_Kasana","date":"July 9, 2025","format":false,"excerpt":"Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally Financial Results: Emcure Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b92,116.00 Crores up from \u20b91,771.00 Crore year on year, a rise of 19.48%. Total Expenses for Q4FY25 of \u20b91,850.00 Crores up from \u20b91,616.00 Crores year on year, a\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168473,"url":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q4fy25-11-rise-in-profits\/","url_meta":{"origin":168657,"position":2},"title":"Torrent Pharmaceuticals Ltd Q4FY25; 11% rise in Profits","author":"Chirag Gupta","date":"May 21, 2025","format":false,"excerpt":"Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. Financial Results: Torrent Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b92,959.00 Crores up from \u20b92,745.00 Crore year on year, a rise of 7.8%. Total Expenses for Q4FY25 of\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/2-11.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/2-11.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/2-11.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/2-11.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/2-11.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/2-11.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169169,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q4fy25-6-rise-in-revenue-2\/","url_meta":{"origin":168657,"position":3},"title":"Glenmark Pharmaceuticals Ltd Q4FY25; 6% rise in Revenue","author":"Divyansh_Kasana","date":"July 17, 2025","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b93,256.20 Crores up from \u20b93,062.96 Crore year on year, a rise of 6.31%. Total Expenses for Q4FY25\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168645,"url":"https:\/\/alphastreet.com\/india\/jubilant-pharmova-ltd-q4fy25-10-rise-in-revenue\/","url_meta":{"origin":168657,"position":4},"title":"Jubilant Pharmova Ltd Q4FY25; 10% rise in Revenue","author":"Chirag Gupta","date":"June 4, 2025","format":false,"excerpt":"Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs. Financial Results: Jubilant Pharmova Ltd reported Revenues for Q4FY25 of \u20b91,929.00 Crores up from \u20b91,759.00 Crore year on year, a rise of 9.66%. Total Expenses for\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169156,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q4fy25-6-rise-in-revenue\/","url_meta":{"origin":168657,"position":5},"title":"Glenmark Pharmaceuticals Ltd Q4FY25; 6% rise in Revenue","author":"Divyansh_Kasana","date":"July 16, 2025","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b93,256.20 Crores up from \u20b93,062.96 Crore year on year, a rise of 6.31%. Total Expenses for Q4FY25\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/168657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=168657"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/168657\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/168658"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=168657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=168657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=168657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}